• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Investigation Report on China's Tiotropium Bromide Market, 2009-2018 Product Image

Investigation Report on China's Tiotropium Bromide Market, 2009-2018

  • ID: 2770920
  • March 2014
  • Region: China
  • 40 Pages
  • China Research & Intelligence

As the air becomes more contaminated, incidence of asthma and chronic obstructive pulmonary diseases also increases. Consequently, more market space is provided for relevant drug manufacturers.

Asthma is a common multiple disease mainly caused by inheritance and environment factors. Recurrent attacks of asthma can lead to complications such as chronic obstructive pulmonary disease, emphysema, cor pulmonale, heart failure and respiratory failure. Sometimes it can endanger patients' lives.

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease that is not fully reversible. It includes chronic bronchitis and emphysema. Pathogens include smoking, air pollution, small airway infection and pneumoconiosis. There are approximately 600 million people worldwide suffering from chronic obstructive pulmonary diseases. According to WHO, COPD is the fourth biggest killer among diseases worldwide. It ranks the same with AIDS after heart diseases, cerebrovascular diseases and acute pulmonary infection. There are over 200 million COPD patients in the world now, and its mortality rate continues to rise year after year. More than 3 million people die of this disease READ MORE >

Note: Product cover images may vary from those shown

1 Relevant Concepts of Tiotropium Bromide
1.1 Development Process and Indication
1.2 Sales Status on the Global Market

2 Market Overview of Tiotropium Bromide in China, 2009-2013
2.1 Patent Status and ""Bolar Exception"" in China Patent System
2.2 Major Manufacturers
2.3 Market Size

3 Investigation on Sales Value of Tiotropium Bromide in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region

4 Investigation on Market Share of Major Tiotropium Bromide Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Investigation on Market Size of Tiotropium Bromide by Dosage Form in China, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form

6 Reference Price of Tiotropium Bromide Produced by Different Enterprises in China Hospital Market
6.1 Boehringer Ingelheim
6.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
6.3 Zhejiang Xianju Pharmaceutical Co., Ltd.

7 Major Manufacturing Enterprises in China Tiotropium Bromide Market, 2009-2014
7.1 Boehringer Ingelheim
7.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
7.3 Zhejiang Xianju Pharmaceutical Co., Ltd.

8 Prospect of China Tiotropium Bromide Market, 2014-2018
8.1 Trend of COPD Incidence in China
8.2 Status of Generic Drug
8.3 Forecast on Market Size
8.4 Forecast on Competition Pattern

Selected Charts

Chart Tiotropium Bromide Products Approved to Market in China by 2014
Chart Sales Value of Tiotropium Bromide in Global Market, 2009-2013
Chart Tiotropium Bromide products approved in China Market
Chart Sales Value of Tiotropium Bromide in Hospital Market in China, 2009-2013
Chart Sales Value of Tiotropium Bromide by Region in China, 2009-2013
Chart Market Share of Tiotropium Bromide Enterprises by Sales Value in China, 2009-2013
Chart Price of Tiotropium Bromide Produced by Boehringer Ingelheim in China Hospital Market, 2014
Chart Forecast on Market Size of Hospital-use Tiotropium Bromide in China, 2014-2018

Note: Product cover images may vary from those shown

- Boehringer Ingelheim
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Zhejiang Xianju Pharmaceutical Co., Ltd.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

ALSO AVAILABLE IN THE FOLLOWING LANGUAGES

RELATED PRODUCTS

Our Clients

Our clients' logos